ArticleMolecular therapy. Oncology2025
Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- PIMO: pathway-based interpretable multiomics interactions for multiomics integration.Bioinformatics (Oxford, England) · 2026Article
- Interruption of cross-communication pathways alters the immune cell signature of pancreatic cancer and decreases tumor growth.Cell communication and signaling : CCS · 2026Article
- Silencing Uracil-DNA glycosylase inhibits colorectal cancer progression.Cancer cell international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic reprogramming is an emerging hallmark and promising therapeutic target in cancer, fueling malignant cells and regulating the tumor microenvironment as a metabolic checkpoint. Triple-negative breast cancer (TNBC), an aggressive subtype with poor prognosis, is marked by high recurrence rates and chemotherapy resistance. However, the metabolic heterogeneity and cell-specific metabolic profiles in TNBC remain underexplored. In this study, we analyzed the expression and prognostic impact of 87 metabolic pathways involving 1,668 genes, identifying 104 candidate metabolic checkpoint genes. Using consensus clustering, we uncovered two distinct metabolic subclusters of TNBC patients that exhibited significant differences in survival. We further characterized the differentially expressed genes, mutation profiles, and microenvironmental features between these two clusters. Additionally,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.